Search
La Cantera coaching
Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreLymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial
Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…
Read moreEHA leads Tutorial in Kazakhstan for better understanding of lymphomas
EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.
Read more“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer
Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.
Read moreMyeloproliferative Neoplasms (MPN)
The aims of the SWG are furthering collaboration and sharing knowledge between centers involved in the management of MPN, a focus to develop centers and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was…
Read moreClinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- »